China’s hemophilia B gene therapy: A challenge to pricey drugs—with caveats

Last April, China’s drug regulators greenlit Belief BioMed’s gene therapy for hemophilia B, a rare bleeding disorder. The move marks a milestone: it’s the country’s first approved gene therapy for the condition, and it directly competes with some of the world’s most expensive medicines, like Roche’s $3.5 million Hemgenix.

The approval, confirmed by Endpoints News, signals China’s push to address unmet medical needs with domestically developed advanced therapies. Hemophilia B, caused by a deficiency in clotting factor IX, currently relies on lifelong infusions or prohibitively priced one-time treatments. Belief BioMed’s therapy uses an adeno-associated virus (AAV) vector to deliver a functional copy of the F9 gene, aiming for durable factor IX production.

Yet what the approval doesn’t clarify is critical: pricing and long-term durability. While early signals suggest the therapy could undercut Western alternatives, no official cost has been disclosed. Nor has peer-reviewed data on its sustained efficacy beyond regulatory trials—standard for gene therapies, where effects can wane over years.

The regulatory status here is clear—this is a full approval, not an accelerated or conditional nod. But the clinical relevance for patients today depends on two unresolved factors. First, access: China’s national reimbursement system has yet to include gene therapies, leaving affordability in question. Second, real-world performance. The trial data underpinning approval, while sufficient for regulators, involved a limited sample size—a common constraint in rare-disease studies.

What we don’t know outweighs the hype. There’s speculation that Belief BioMed’s therapy may avoid the liver toxicity seen in some AAV-based treatments, but without head-to-head comparisons or long-term registries, that’s unproven. The company has planned post-marketing studies, yet their scope and transparency remain undefined.

For now, this is a step forward in expanding options, not a paradigm shift. The real signal isn’t the approval itself—it’s whether China can balance innovation with the practical demands of cost and durability, where even approved gene therapies often stumble.

In other words, this approval confirms China’s regulatory agility, not yet a patient victory. The therapy’s safety and mechanism are plausible, but its place in clinical practice hinges on data still to come—data that will determine if ‘affordable’ and ‘effective’ can coexist in the same sentence.